What Remedica Ltd. does

Remedica Ltd. is a Cyprus-headquartered generic pharmaceutical manufacturer founded in 1980, operating three specialized manufacturing facilities spanning 55,000 sqm in Limassol with EU-GMP certification and approvals from stringent regulators including Germany, the UK, Denmark, Australia, Brazil, Japan, Saudi Arabia (SFDA), and New Zealand (MEDSAFE). The company markets a portfolio of 300+ generic, branded generic, and OTC products across 16 therapeutic areas — notably oncology, cardiovascular, CNS, anti-infectives, and diabetes — and has manufactured specialized lines for antibiotics, hormonal, and oncological products. Technical capabilities include solid, semi-solid, liquid, and aerosol dosage forms, advanced automation and robotics, and serialization/aggregation systems for EU anti-counterfeiting compliance. Recent capex includes KorschXL400 compression machines and a new Export Logistics Centre (B12).

Remedica operates four parallel go-to-market models: B2B dossier out-licensing of EU-origin pharmaceutical files to multinational and regional pharma partners; B2C commercialization of branded generics and OTC products through a 25+ rep sales force covering 100% of Cypriot pharmacies and select international markets; humanitarian supply to 25+ NGOs including UNICEF, WHO, Red Cross, MSF, and UNRWA; and clinical-trial comparator/placebo supply. International footprint includes scientific/sales offices in UAE, Saudi Arabia, Vietnam, Greece, and Kenya, with commercial presence in 80+ markets and exports to 140+ countries. The B2C model was extended in 2023 into medical devices and cosmetics (RemeHeal, RemAthlon, RemeFreeze, RemeFoot, RemeSaline) distributed exclusively through pharmacies, and in 2024 with the OTC launch of Edolfen (ibuprofen/paracetamol combination).

Pricing is contract-based and not publicly disclosed; the B2B dossier business reportedly achieves a 100% contract renewal rate with established blue-chip customers. In 2024–2025 the company executed the AJA Pharma (Saudi Arabia) technology-transfer MoU, achieved PSCI Partner status, signed an MoU with the University of Nicosia, opened the new Export Logistics Centre, and appointed a new CEO (Andrew Bird, April 2025) signalling a renewed international expansion mandate. Remedica is privately held, with no disclosed parent company, funding rounds, or institutional investors in the available data.

Name

Remedica Ltd.

Legal name

Remedica Ltd.

Website

https://remedica.eu

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Remedica Ltd. is a Cyprus-based generic pharmaceutical manufacturer founded in 1980, producing 300+ generics, branded generics, and OTC products across 16 therapeutic areas for B2B dossier licensing, B2C pharmacy distribution, NGO humanitarian supply, and clinical-trial clients in 140+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Dossier licensing
• Medical devices
• OTC products

Headquarters

HQ city

Limassol

HQ country

Cyprus

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. B2B Dossier Out-Licensing: Remedica develops pharmaceutical dossiers in compliance with EU regulations and out-licenses them to international partners including multinational corporations and regional players. Achieves a consistent 100% contract renewal rate with established blue-chip customers. Manufacturing facilities are EU-GMP certified and accredited by strict regulatory authorities worldwide.
2. B2C Product Sales: Direct commercialization of own branded generic, branded generic, and OTC products in Cyprus and international markets including Eastern EU, Middle East, Africa, LATAM, Asia, Australia/New Zealand. Products distributed through network of local pharmacies and healthcare professionals.
3. NGO Supply: Supplying pharmaceutical products to over 25 NGOs globally including UNICEF, WHO, Red Cross, Doctors Without Borders, and UNRWA. First medicine shipments began in the 1990s. Products provided to war-stricken and impoverished communities worldwide.
4. Clinical Trial Supply: Providing comparator drugs, pharmaceutical auxiliaries and placebo products to support clinical trials across international markets. Manufacturing facilities comply with EU GMP standards, ensuring highest quality and safety for clinical use.
5. Medical Devices and Cosmetics: Since 2023, Remedica has entered the market for medical devices, cosmetics, and other non-pharmaceutical products including RemeHeal Gel, RemAthlon Spray, RemeFreeze Spray, RemeFoot, and RemeSaline Nasal Spray — sold exclusively through pharmacies.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels10 records

Core offering

Remedica develops, manufactures, and distributes a portfolio of over 300 generic, branded generic, and OTC pharmaceutical products across 16 therapeutic areas (oncology, cardiovascular, CNS, anti-infectives, diabetes) from EU-GMP certified facilities in Limassol, Cyprus. The company operates through multiple business models including B2B dossier out-licensing to international pharmaceutical partners, B2C commercialization of branded products through pharmacy networks, NGO supply for humanitarian organizations, and clinical trial supply of comparator drugs. In 2023 it expanded into medical devices and cosmetics distributed exclusively through pharmacies.

Product overview

Remedica Ltd. is a global generics pharmaceutical company headquartered in Cyprus, operating a multi-product portfolio platform comprising over 300 generic pharmaceutical products across 16 therapeutic areas, a growing line of medical devices and cosmetics (including RemeHeal Gel, RemAthlon Spray, RemeFreeze Spray, RemeFoot, RemeSaline Nasal Spray), and OTC products like Edolfen. The company operates through three distinct business models: B2B dossier out-licensing and supply to pharmaceutical partners, B2C commercialization of branded products in international markets and Cyprus, and NGO supply for humanitarian purposes. Manufacturing capabilities span solid dosage forms (tablets, capsules), semi-solids (gels, creams, ointments), liquids (syrups, powders), topical aerosols, and suppositories, with serialization and aggregation capabilities for regulatory compliance. The portfolio focuses on high-demand therapeutic areas including Oncology, Cardiovascular/Metabolic, CNS, Anti-infectives, and Musculoskeletal treatments.

Differentiator

Problem solved

Functional benefit

Brands

• RemAthlon: Cosmetic product line including muscle spray for relief of muscle stiffness and pain. RemAthlon Muscle Spray was the Name Sponsor of the 5KM City Race at Limassol Marathon 2024.
• Edolfen
• RemeHeal
• RemeFreeze
• RemeFoot
• RemeSaline
• RemeRiders

Products and services

• Generic Pharmaceutical Products
• B2B Dossier Out-Licensing Portfolio
• B2C Branded Pharmaceutical Portfolio
• Oncology Products
• Cardiovascular Products
• CNS Products
• Anti-infective Products
• RemeHeal Gel
• RemAthlon Spray
• RemeFreeze Spray
• RemeFoot
• RemeSaline Nasal Spray
• Edolfen
• Clinical Trial Supply
• NGO Supply of Essential Medicines

Quantifiable outcome

• Over 22% market share in therapeutic areas of operation in Cyprus
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• University of NicosiacoreStrategic or Co-development Partner · 30 May 2025Remedica signed a Memorandum of Understanding (MoU) with the University of Nicosia on May 30, 2025. The partnership bridges academic excellence with industry expertise, aiming to promote Scientific Research and Education in Pharmaceutical Science. Focus areas include joint research programs, conferences, seminars and scientific events, and strengthening practical training and professional education for Pharmacy students.
• AJA PharmacoreStrategic or Co-development Partner · 25 October 2024Remedica signed a non-binding MoU with AJA Pharma (a subsidiary of Saudi Chemical Company Holding - SCCH) during CPHI Milan in October 2024. The partnership focuses on developing medicines and transferring technology to drive innovation and enter new markets, particularly in Oncology, Cardiovascular, and Diabetes therapeutic areas in both tablets and injectables. The Saudi market is recognized for its rapid growth and strategic geographic position under Vision 2030 reform plan.
• Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development Partner · 1 August 2024Remedica achieved PSCI Partner status, committing to PSCI Principles on Environment, Ethics, Human Rights, Health and Safety, and Governance and Management Systems. PSCI is an association of global pharmaceutical and healthcare companies promoting responsible practices throughout the supply chain.
• EuroCons GroupcoreImplementation/ SI/ Consulting Partner · 31 July 2024Remedica signed a new contract with EuroCons Group to support the innovative 'Factory in Factory' project. EuroCons delivers a turnkey solution including installation of cleanroom technology and new equipment. This partnership is part of Remedica's transformation and roadmap to success, with EuroCons understanding Remedica's new standards and ambitious projects.
• UNICEFcoreStrategic or Co-development PartnerLong-term supply partnership with UNICEF for delivery of life-saving medicines to populations in need. Collaboration dates back to the 1990s. UNICEF is one of over 25 NGOs supplied by Remedica.
• WHO (World Health Organization)coreStrategic or Co-development PartnerLong-term supply partnership with WHO for essential medicines. One of the major NGO partners supplied by Remedica globally.
• Red CrosscoreStrategic or Co-development PartnerLong-term humanitarian supply partnership with the Red Cross for life-saving medicines to war-stricken and impoverished communities.
• Doctors Without Borders (Médecins Sans Frontières)coreStrategic or Co-development PartnerLong-term supply partnership providing pharmaceutical products to support MSF's humanitarian medical missions globally.
• UNRWAcoreStrategic or Co-development PartnerLong-term supply partnership with UNRWA (United Nations Relief and Works Agency) for Palestine refugees, supporting humanitarian healthcare delivery.
• CPHI (institutional event)minorGTM or Marketing PartnerRemedica participates in CPHI, the world's largest pharmaceutical event (Milan 2024, Barcelona 2023), with a dedicated booth. CPHI brings together 60,000+ pharmaceutical professionals from around the world for networking, partnership building, and market expansion opportunities.
• European University CyprusminorStrategic or Co-development PartnerGrowing partnership with European University Cyprus. Pharmacy school students visit Remedica's state-of-the-art facilities. Partnership includes HR presentations, Drug Registration Department presentations on career opportunities, and tours of manufacturing plants and Quality Control Department.

Scale indicators10 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with a similar mid-sized European platform, broad therapeutic-area portfolio, strong international export footprint, and in-house API and finished-dose manufacturing — directly comparable in business model and scale to Remedica.
• Polpharma Group: Polish generic pharmaceutical manufacturer with EU-GMP facilities, broad solid-dose portfolio across cardiovascular, CNS, and oncology, and active exports into CIS, MENA, and Eastern Europe — directly comparable geographic and therapeutic footprint.
• Hikma Pharmaceuticals: Jordan- and UK-headquartered generic and specialty pharmaceutical manufacturer serving MENA, US, and emerging markets with a branded-generics model and in-house manufacturing — closely comparable geographic and product mix to Remedica's dossier licensing and emerging-markets commercialization.
• Stada Arzneimittel: German-headquartered European generics and consumer-health company with multi-country commercial footprint, EU manufacturing footprint, and active dossier/portfolio licensing — comparable operating model though materially larger than Remedica.

Broad incumbents

• Sandoz: Novartis-spun-off European-headquartered global generics business with extensive EU manufacturing, broad therapeutic-area coverage, and global commercial reach — a direct competitor in dossier licensing and B2B generics supply, materially larger.
• Viatris: US-headquartered global off-patent medicines company (Mylan-Upjohn combination) with broad generic portfolio and worldwide distribution — overlaps with Remedica in B2B dossier licensing, comparator supply, and emerging-markets commercialization at significantly larger scale.
• Aurobindo Pharma: Indian-headquartered global generic manufacturer with EU-GMP facilities, large-scale API and finished-dose production, and broad emerging-markets footprint — a key cost-side competitor to Remedica in dossier licensing and NGO-supply tenders.
• Teva Pharmaceutical Industries: Israeli-headquartered global generic pharmaceutical leader with the broadest generic portfolio worldwide and active dossier licensing; competes with Remedica across most therapeutic areas but at far greater scale and with US-focused distribution.

Emerging players

• Glenmark Pharmaceuticals: Indian-headquartered generic and specialty pharmaceutical company with growing EU and emerging-markets presence, dossier-based partnerships, and active branded-generics commercialization — a partial overlap peer in business model, smaller than the incumbents but comparable in aspiration.

Others

• HELM AG: German-headquartered global pharmaceutical distribution and dossier licensing family-owned company, active in MENA, Africa, and CIS — overlaps with Remedica in distribution partnerships, dossier licensing to regional partners, and emerging-markets pharma supply, though more distribution-led than manufacturing-led.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/RemedicaLtd
• Facebookfacebook.com/129161903800033
• LinkedInlinkedin.com/company/remedica-ltd_2
• Instagraminstagram.com/remedica.eu
• Xx.com/Remedica

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remedica Ltd.